Polivy
(Polatuzumab Vedotin)Phase 3Antibody–drug conjugate
RochePolatuzumab vedotin is used to treat certain types of blood cancers, specifically a form of lymphoma called diffuse large B-cell lymphoma, usually in combination with other chemotherapy drugs.[1] Polivy is currently being investigated across 23 indications[3], with its most advanced program in Phase 3.[1]
Polivy is one of 386 small molecule programs targeting Follicular Lymphoma. It is currently in Phase 3.
23
Indications
69
Total Trials
50
Active Trials
385
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 23 indications
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Polivy
RochePhase 3
Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
R-CHOP
IIncyte Biosciences Japan GK
Preclinical
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diffuse Large B-Cell Lymphoma20 trials
Show 17 more trials
Lymphoma13 trials
Show 10 more trials
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Recruiting·—·Phase 1·NCT06730542·20 enrolled
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05798156·125 enrolled
Efficacy and Safety2 trials
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled
25 more indications
Mantle Cell Lymphoma2 trials
Richter's Transformation2 trials
Large B-cell Lymphoma2 trials
Non-Hodgkin Lymphoma2 trials
Phase II1 trial
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07034508·134 enrolled
Elderly Patients1 trial
Treatment1 trial
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Recruiting·—·Phase 2·NCT06530511·30 enrolled
B-cell non-Hodgkins lymphoma1 trial
Newly Diagnosed1 trial
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Enrolling by invitation·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06468943·20 enrolled
DLBCL1 trial
Aggressive Non-Hodgkin Lymphoma1 trial
Hodgkin Lymphoma1 trial
Lymphoma, Large B-Cell, Diffuse1 trial
Diffuse Large B-Cell Lymphoma Unclassifiable1 trial
Lymphoma, Non-Hodgkin1 trial
Large B-Cell Lymphoma (LBCL)1 trial
Lymphoma, B-Cell1 trial
B-cell Non Hodgkin Lymphoma1 trial
Non-Hodgkins Lymphoma1 trial
Post-Transplant Lymphoproliferative Disorder1 trial
A Phase I/II Study of Frontline Therapy With Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT06040320·12 enrolled
Regulatory
FDA Approval Timeline[4]
Jun 10, 2019
POLIVY
BLA BLA761121
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Polatuzumab Vedotin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]